Castle Biosciences (CSTL) Accounts Payables (2018 - 2026)

Castle Biosciences has disclosed Accounts Payables across 9 years of filings, most recently posting $15.0 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $15.0 million, up 76.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.0 million (up 76.88% YoY), and the FY2025 annual result was $18.7 million, up 171.13% from the prior year.
• Accounts Payables came in at $15.0 million for Q1 2026 at Castle Biosciences, down from $18.7 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $18.7 million in Q4 2025 to a low of $3.3 million in Q2 2022.
• The 5-year median for Accounts Payables is $8.5 million (2025), against an average of $8.9 million.
• Across the five-year window, Accounts Payables jumped 200.57% in 2023 and plunged 32.79% in 2024, its largest moves.
• Castle Biosciences' Accounts Payables stood at $4.7 million in 2022, then soared by 117.04% to $10.3 million in 2023, then sank by 32.79% to $6.9 million in 2024, then jumped by 171.13% to $18.7 million in 2025, then fell by 19.63% to $15.0 million in 2026.
• The last three Accounts Payables figures came in at $15.0 million (Q1 2026), $18.7 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.